Common Equity: The sum of all common equity items.
PURE Bioscience (PURE) had Common Equity of $-6.27M for the most recently reported fiscal quarter, ending 2026-01-31.
| Income Statement Financials | |
$0.44M |
|
$-0.79M |
|
$0.21M |
|
$0.24M |
|
$1.13M |
|
$-0.68M |
|
$-0.10M |
|
$-0.79M |
|
$-0.79M |
|
$-0.79M |
|
$-0.79M |
|
$-0.79M |
|
$-0.79M |
|
$-0.68M |
|
$-0.68M |
|
111.89M |
|
111.89M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$0.78M |
|
$0.01M |
|
$0.01M |
|
$0.79M |
|
$3.06M |
|
$4.01M |
|
$4.01M |
|
$7.06M |
|
|
Common Equity |
$-6.27M |
$-6.27M |
|
$-6.27M |
|
111.89M |
|
| Cash Flow Statement Financials | |
$-0.86M |
|
-- |
|
$0.72M |
|
$0.41M |
|
$0.27M |
|
$-0.14M |
|
$0.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.26 |
|
-- |
|
-- |
|
-1.77 |
|
-0.98 |
|
53.60% |
|
-153.83% |
|
-153.83% |
|
-- |
|
-176.80% |
|
-176.80% |
|
$-0.86M |
|
-- |
|
-- |
|
-- |
|
0.56 |
|
0.84 |
|
1.76 |
|
51.08 |
|
12.51% |
|
12.51% |
|
-99.62% |
|
34.63% |
|
$-0.06 |
|
$-0.01 |
|
$-0.01 |
|